Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The employee awards carry a $88.32 exercise price and vest over the first anniversary and the following 36 months.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Dianthus Therapeutics (DNTH) granted equity inducement awards to six newly hired, non-executive employees to support their acceptance of employment.

Granted on October 1, 2026, the awards comprise options to purchase 106,000 common shares at an exercise price of $88.32 per share, with a 10-year term. The options vest 25% on the first anniversary of the vesting commencement date, then in equal monthly installments over the following 36 months. The independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4). The awards are subject to the company's Equity Inducement Plan and stock option agreement.

Positive

None.

Negative

Minor point. Forward-looking: it has not happened yet and may not happen.Options for 106,000 common shares at $88.32 per share create potential dilution upon exercise.

Key Figures

Aggregate option shares: 106,000 shares Exercise price: $88.32 per share Option term: 10 years +1 more

Aggregate option shares: 106,000 shares; Inducement grants to six newly hired employees
Exercise price: $88.32 per share; Non-qualified stock options
Option term: 10 years; Non-qualified stock options
Vesting schedule: 25% on the first anniversary, then equal monthly installments for 36 months; Options

Historical Context

1 past event · Latest: Sep 02

1 event

Sep 02
Inducement grants

24h Move

+1.5%

Prior grant: 52,000 options for four hires, with a 10-year term and $106.62 exercise price.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4)

2 terms

non-qualified stock options financial

"non-qualified stock options to purchase an aggregate of 106,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/01/2026 - 05:00 PM

NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 106,000 shares of the Company's common stock with a 10-year term and an exercise price of $88.32 per share. The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity inducement awards did Dianthus Therapeutics grant to new employees?

Dianthus granted six newly hired, non-executive employees options to purchase an aggregate of 106,000 common shares on October 1, 2026. The options have an exercise price of $88.32 per share and a 10-year term.

How do Dianthus Therapeutics' October 2026 inducement options vest?

The options vest 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. They are subject to the company's Equity Inducement Plan and stock option agreement.

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)